EBV ZEBRA Antibody (BZ1): sc-53904

EBV ZEBRA Antibody (BZ1) is a mouse monoclonal IgG1 kappa light chain antibody that detects the EBV ZEBRA protein of EBV origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-EBV ZEBRA antibody (BZ1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The EBV ZEBRA protein, also known as BamHI Z fragment leftward open reading frame 1, plays a pivotal role in the life cycle of the Epstein-Barr virus, which is a member of the herpesvirus family and one of the most prevalent human viruses. ZEBRA functions as a transcriptional transactivator that regulates the switch between the latent and lytic phases of the virus. During latency, ZEBRA expression remains suppressed, but upon stimulation, ZEBRA synthesis leads to the activation of several early viral genes essential for viral replication. This regulatory mechanism allows the virus to reactivate and replicate in response to specific cellular signals, contributing to the pathogenesis of EBV-associated diseases, including certain lymphomas and nasopharyngeal carcinoma. ZEBRA′s ability to bind to specific DNA sequences underscores its importance in modulating viral gene expression and highlights its potential as a target for therapeutic interventions aimed at controlling EBV-related malignancies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EBV ZEBRA Antibody (BZ1) References:

1. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.  |  Fahmi, H., et al. 2000. J Virol. 74: 5810-8. PMID: 10846060
2. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion.  |  Hahn, P., et al. 2001. Int J Cancer. 91: 815-21. PMID: 11275985
3. Cytokine signaling and Epstein-Barr virus-mediated cell transformation.  |  Mosialos, G. 2001. Cytokine Growth Factor Rev. 12: 259-70. PMID: 11325606
4. The switch between latency and replication of Epstein-Barr virus.  |  Miller, G. 1990. J Infect Dis. 161: 833-44. PMID: 2157769
5. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.  |  Young, LS., et al. 1988. J Gen Virol. 69 (Pt 5): 1051-65. PMID: 2836550
6. Replacing C189 in the bZIP domain of Zta with S, T, V, or A changes DNA binding specificity to four types of double-stranded DNA.  |  Ray, S., et al. 2018. Biochem Biophys Res Commun. 501: 905-912. PMID: 29772230
7. Utility of Serum EB Virus Zta Antibody in the Diagnostic of Nasopharyngeal Carcinoma: Evidences From 2,126 Cases and 15,644 Controls.  |  Zhang, G., et al. 2019. Front Oncol. 9: 1391. PMID: 31921648
8. Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.  |  Zhao, M., et al. 2020. J Virol. 94: PMID: 32847852
9. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.  |  Chen, Y., et al. 2021. Int J Cancer. 149: 1109-1120. PMID: 33899230
10. Construction of rBCG carrying the IL-2-BZLF1 fusion gene and its immunological function.  |  Yu, M., et al. 2024. Appl Microbiol Biotechnol. 108: 19. PMID: 38170315
11. Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers.  |  Wu, M., et al. 2024. Nat Commun. 15: 3729. PMID: 38702330
12. The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins.  |  Gao, Z., et al. 1998. J Virol. 72: 8559-67. PMID: 9765394

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-EBV ZEBRA Antibody (BZ1) has 142 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

EBV ZEBRA Antibody (BZ1) Specifications

Alternate Product Name: BZLF1

Product Clone Name: BZ1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: EBV ZEBRA

Epitope Species: EBV

Product Reactivity/Detection: ZEBRA

Species Reactivity/Detection: EBV

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 142 citations in various scientific publications

Available Conjugates/Forms for EBV ZEBRA Antibody (BZ1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin